BioSpace News Archive

Matinas BioPharma Holdings, Inc., announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investor conferences.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, announced it has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced the recent issuance of three additional patents in the United States and Europe.

Michael Freeman, CEO/CTO of Ocutrx Vision Technologies, LLC, a California-based technology company developing state-of-the-art augmented reality headset devices, will be delivering a highly anticipated keynote speech that will discuss the Surgery Suite of the Future, including the application of Augmented/Extended Reality, “glasses-free” 3D monitors, 5G Edge Computing for hospitals, and Artificial Intelligence.

BioCardia®, Inc. announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Oncolytics Biotech® Inc. announced the first patient has been dosed in the Company’s investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer.

Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, announced the completion of an oversubscribed $18.4 million private financing round.

Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise.

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, announced that the IMV’s executive management team will participate at four upcoming virtual investor conferences in September:

COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC)